NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2024. Filed Dec 17, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 17, 2024
NMTC$0.89+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Years ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Product revenue | $3,453,003 | $1,952,441 |
| Cost of product revenue | 2,373,336 | 1,495,924 |
| Product gross profit | 1,079,667 | 456,517 |
| Collaborations revenue | — | 1,455,188 |
| Operating expenses: | ||
| Selling, general and administrative | 7,901,695 | 6,926,269 |
| Research and development | 5,065,181 | 6,940,686 |
| Total operating expenses | 12,966,876 | 13,866,955 |
| Loss from operations | (11,887,209) | (11,955,250) |
| Fair value change in warrant liability | (327,092) | — |
| Financing costs | (228,988) | — |
| Other income, net | 125,179 | 95,759 |
| Loss before income taxes | (12,318,110) | (11,859,491) |
| Provision for income taxes | — | — |
| Net loss | $(12,318,110) | $(11,859,491) |
| Net loss per share: | ||
| Basic and diluted | $(0.46) | $(0.65) |
| Number of shares used in per share calculations: | ||
| Basic and diluted | 26,762,392 | 18,121,108 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.